Akums Drugs & Pharma has debuted at Rs 725.00 on the BSE, up by 46 points or 6.77% from its issue price of Rs 679.00.
The scrip is currently trading at Rs 762.65, up by 83.65 points or 12.32% from its issue price.
It has touched a high and low of Rs 784.65 and Rs 724.50 respectively. So far 5.96 lakh shares were traded on the counter.
The offering, which was open for subscription between July 30, 2024 and August 01, 2024 was subscribed 63.56 times. The issue price was fixed at Rs 679.00 per share i.e. at upper end of price band of Rs 646-679 apiece.
Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: